Predict your next investment

GMS Holdings company logo
Holding Company
FINANCIAL | Investment Firms & Funds
gmsholdings.com

See what CB Insights has to offer

Investments

2

Partners & Customers

1

About GMS Holdings

GMS Holdings is a holding company for a group of diversified businesses and assets around the world. The company's investments span several geographies and industries in both the private and public domains. The company operates through three main subsidiaries, which are GMS Specialized Services, GMS Ventures & Investments and GMS Real Estate.

GMS Holdings Headquarter Location

7th Circle Zahran Plaza Building, 4th Floor Zahran Street

Amman, 11844,

Jordan

+962 6 5827999

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

GMS Holdings Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

GMS Holdings Rank

Latest GMS Holdings News

TPG Growth leads Series C funding in Strides’ biopharma division

Mar 19, 2021

By SHARE Stelis Biopharma, a division of Mumbai-listed Strides Pharma Science, has raised $125 million (Rs 907 crore) as part of its Series C round led by TPG Growth. Route One, Think Investments and the Mankekar Family also participated in this round that has given Stelis a post-money valuation of $350 million (Rs 2,537 crore), said Strides in a stock market disclosure. The Series C funding comprises a primary capital infusion of $85 million and a secondary placement of $40 million for existing shareholder GMS Holdings. Arun Kumar, founder of Strides Group, said that GMS will continue to be its shareholder post the secondary placement. Strides also said that Stelis closed its Series B funding at $70 million . The family office of Strides led this round. Stelis had kicked off the process to raise Series B funding in 2018 and it had achieved the first close of the round at $35 million. Post the Series C funding, Strides will hold 33% in Stelis. It also plans to demerge and list its biopharma business under Stelis, it added without specifying any timeline. The company will use the funds raised from these rounds to complete its last mile capex for the contract development and manufacturing organisation (CDMO) business, and ramp up its process development lab and other technical capabilities. Part of the funds will also be deployed to build its vaccine block infrastructure, pay debt and for other general corporate purposes. Bengaluru-based Stelis is a vertically integrated biopharmaceutical company with R&D, process scale-up and end-to-end manufacturing capabilities. Stelis was earlier a fully owned subsidiary of Strides Pharma, which was formerly called Strides Shasun Ltd. In 2014, the company agreed to sell a 25.1% stake in Stelis to GMS Holdings for $21.9 million. TPG’s healthcare deals  The PE firm has invested $14 billion of equity capital in the healthcare sector across the world. Of this, 20% has been invested outside the US. In 2017, TPG Growth set up a separate healthcare platform – Asia Healthcare Holdings (AHH) – to invest in single-speciality hospitals. Asia Healthcare invested in Cancer Treatment Services International, Motherhood hospital chain operator Rhea Healthcare and Nova IVI Fertility Pvt. Ltd in India. Last year, AHH agreed to sell Cancer Treatment Services to New York-listed Varian Medical Systems Inc. for $283 million, earning a handsome return. TPG Growth had previously invested directly in medical devices maker Healthium MedTech (formerly Sutures India), which it sold to Apax Partners in 2018. Its parent TPG has a stake in hospital chain Manipal Hospitals. Its other healthcare investments outside the US include Parkway Holdings (Singapore), Healthscope (Australia), Asiri Health (Sri Lanka) and United Family Healthcare (China). Earlier last year, TPG Growth increased its exposure to a bulk-drugs company Solara Active Pharma Sciences Ltd.

GMS Holdings Investments

2 Investments

GMS Holdings has made 2 investments. Their latest investment was in Stelis Biopharma as part of their Series C on March 3, 2021.

CBI Logo

GMS Holdings Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

3/19/2021

Series C

Stelis Biopharma

$125M

Yes

4

10/16/2017

Unattributed

Subscribe to see more

$99M

Subscribe to see more

10

Date

3/19/2021

10/16/2017

Round

Series C

Unattributed

Company

Stelis Biopharma

Subscribe to see more

Amount

$125M

$99M

New?

Yes

Subscribe to see more

Co-Investors

Sources

4

10

GMS Holdings Partners & Customers

1 Partners and customers

GMS Holdings has 1 strategic partners and customers. GMS Holdings recently partnered with Outlook Therapeutics on September 9, 2017.

Date

Type

Business Partner

Country

News Snippet

Sources

9/8/2017

Licensor

Outlook Therapeutics

United States

Oncobiologics announces strategic partnership with GMS Tenshi Holdings Pte. Limited

In connection with the entry into the Purchase Agreement , Oncobiologics and GMS Tenshi also entered into a Joint Development and License Agreement , providing for the license to GMS Tenshi of rights to ONS-3010 and ONS-1045 in emerging markets , excluding China , India and Mexico .

1

Date

9/8/2017

Type

Licensor

Business Partner

Outlook Therapeutics

Country

United States

News Snippet

Oncobiologics announces strategic partnership with GMS Tenshi Holdings Pte. Limited

In connection with the entry into the Purchase Agreement , Oncobiologics and GMS Tenshi also entered into a Joint Development and License Agreement , providing for the license to GMS Tenshi of rights to ONS-3010 and ONS-1045 in emerging markets , excluding China , India and Mexico .

Sources

1

GMS Holdings Team

2 Team Members

GMS Holdings has 2 team members, including current Chief Executive Officer, Faisal Sukhtian.

Name

Work History

Title

Status

Ghiath Sukhtian

Founder

Current

Faisal Sukhtian

Chief Executive Officer

Current

Name

Ghiath Sukhtian

Faisal Sukhtian

Work History

Title

Founder

Chief Executive Officer

Status

Current

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.